ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus

ClinicalTrials.gov ID: NCT00765817

Public ClinicalTrials.gov record NCT00765817. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 22, 2026, 11:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized Trial Comparing Exenatide With Placebo in Subjects With Type 2 Diabetes on Insulin Glargine With or Without Oral Antihyperglycemic Medications

Study identification

NCT ID
NCT00765817
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
AstraZeneca
Industry
Enrollment
261 participants

Conditions and interventions

Interventions

  • exenatide Drug
  • placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 30, 2008
Primary completion
Dec 31, 2009
Completion
Dec 31, 2009
Last update posted
Oct 23, 2016

2008 – 2010

United States locations

U.S. sites
40
U.S. states
23
U.S. cities
40
Facility City State ZIP Site status
Research Site Peoria Arizona
Research Site Phoenix Arizona
Research Site Buena Park California
Research Site Concord California
Research Site Fresno California
Research Site Greenbrae California
Research Site La Mesa California
Research Site Lancaster California
Research Site Northridge California
Research Site Palm Springs California
Research Site Salinas California
Research Site Hollywood Florida
Research Site Jacksonville Florida
Research Site Atlanta Georgia
Research Site Honolulu Hawaii
Research Site Idaho Falls Idaho
Research Site Des Moines Iowa
Research Site Wichita Kansas
Research Site Baton Rouge Louisiana
Research Site Lafayette Louisiana
Research Site Matairie Louisiana
Research Site Boston Massachusetts
Research Site Minneapolis Minnesota
Research Site Chesterfield Missouri
Research Site St Louis Missouri
Research Site Omaha Nebraska
Research Site Las Vegas Nevada
Research Site Berkeley Heights New Jersey
Research SIte Teaneck New Jersey
Research Site Albuquerque New Mexico
Research SIte New York New York
Research Site Durham North Carolina
Research Site Bend Oregon
Research Site Dallas Texas
Research Site El Paso Texas
Research Site Georgetown Texas
Research Site San Antonio Texas
Research Site Richmond Virginia
Research Site Vancouver Washington
Research Site Kenosha Wisconsin

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 19 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00765817, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 23, 2016 · Synced Apr 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00765817 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →